Literature DB >> 12767806

Construction of a modified vector for efficient purification of recombinant Mycobacterium tuberculosis proteins expressed in Escherichia coli.

Suhail Ahmad1, Maisa M Ali, Abu S Mustafa.   

Abstract

A major problem in assessing the vaccine and diagnostic potential of various proteins encoded by Mycobacterium tuberculosis genome is the inability to produce large quantities of these proteins, even when Escherichia coli or other heterologous systems are employed for recombinant protein production. To overcome these barriers, we have constructed a modified expression vector, using pGEX-4T-1 vector as the backbone. In addition to the features offered by the pGEX-4T vectors, the new vector allowed easy purification of recombinant proteins on the highly versatile Ni-NTA-agarose affinity matrix. The utility of the new vector was demonstrated by expressing and purifying, to near homogeneity, two M. tuberculosis proteins, i.e., Rv3872 (a member of the multi-gene PE subfamily) and Rv3873 (a member of the multi-gene PPE subfamily), which are encoded by the RD1 region of M. tuberculosis. The proteins encoded by rv3872 and rv3873 were expressed at high levels as fusion proteins with glutathione-S-transferase in E. coli. The recombinant Rv3872 and Rv3873 proteins were purified and isolated free of the fusion partner (GST) by affinity purification on glutathione-Sepharose and/or Ni-NTA-agarose affinity matrix and cleavage of the purified fusion proteins by thrombin protease. The recombinant Rv3872 protein was nearly homogeneous (more than 95% pure) while Rv3873 preparation was more than 90% pure. The recombinant Rv3872 and Rv3873 proteins were immunologically active and reacted with antibodies in sera from TB patients. Our results demonstrate the utility of the newly constructed expression vector with two affinity tags for efficient expression and purification of recombinant M. tuberculosis proteins expressed in E. coli, which could be used for further diagnostic and immunological studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767806     DOI: 10.1016/s1046-5928(03)00052-4

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  6 in total

1.  Comparative evaluation of INNO-LiPA HBV assay, direct DNA sequencing and subtractive PCR-RFLP for genotyping of clinical HBV isolates.

Authors:  Maisa M Ali; Fuad Hasan; Suhail Ahmad; Widad Al-Nakib
Journal:  Virol J       Date:  2010-05-30       Impact factor: 4.099

2.  Cellular immune responses to recombinant Mycobacterium bovis BCG constructs expressing major antigens of region of difference 1 of Mycobacterium tuberculosis.

Authors:  Kholoud Shaban; Hanady A Amoudy; Abu S Mustafa
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

Review 3.  In silico analysis and experimental validation of Mycobacterium tuberculosis -specific proteins and peptides of Mycobacterium tuberculosis for immunological diagnosis and vaccine development.

Authors:  Abu Salim Mustafa
Journal:  Med Princ Pract       Date:  2013-08-31       Impact factor: 1.927

4.  The effect of adjuvants and delivery systems on Th1, Th2, Th17 and Treg cytokine responses in mice immunized with Mycobacterium tuberculosis-specific proteins.

Authors:  Hussain A Safar; Abu Salim Mustafa; Hanady A Amoudy; Ahmed El-Hashim
Journal:  PLoS One       Date:  2020-02-06       Impact factor: 3.240

Review 5.  Immunological Characterization of Proteins Expressed by Genes Located in Mycobacterium tuberculosis-Specific Genomic Regions Encoding the ESAT6-like Proteins.

Authors:  Abu Salim Mustafa
Journal:  Vaccines (Basel)       Date:  2021-01-07

6.  Fusion Molecules of Heat Shock Protein HSPX with Other Antigens of Mycobacterium tuberculosis Show High Potential in Serodiagnosis of Tuberculosis.

Authors:  Ruqyya Khalid; Madeeha Afzal; Sana Khurshid; Rehan Zafar Paracha; Imran H Khan; Muhammad Waheed Akhtar
Journal:  PLoS One       Date:  2016-09-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.